Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (14)

2024

  1. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial

    Clinical Nutrition, Vol. 43, Núm. 7, pp. 1770-1781

2023

  1. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease

    Journal of Physiology and Biochemistry

  2. Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

2022

  1. A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers

    Panminerva medica, Vol. 64, Núm. 4, pp. 485-496

2021

  1. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study

    European Journal of Nutrition, Vol. 60, Núm. 6, pp. 3043-3057

  2. Three different genetic risk scores based on fatty liver index, magnetic resonance imaging and lipidomic for a nutrigenetic personalized management of nafld: The fatty liver in obesity study

    Diagnostics, Vol. 11, Núm. 6

2020

  1. Association of the SH2B1 RS7359397 gene polymorphism with steatosis severity in subjects with obesity and non-alcoholic fatty liver disease

    Nutrients, Vol. 12, Núm. 5

2019

  1. Association between sleep disturbances and liver status in obese subjects with nonalcoholic fatty liver disease: A comparison with healthy controls

    Nutrients, Vol. 11, Núm. 2

2018

  1. Interaction between an ADCY3 genetic variant and two weight-lowering diets affecting body fatness and body composition outcomes depending on macronutrient distribution: A randomized trial

    Nutrients, Vol. 10, Núm. 6

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

2011

  1. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma

    Functional and Integrative Genomics, Vol. 11, Núm. 3, pp. 419-429

  2. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

  2. Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis

    Vaccine, Vol. 28, Núm. 44, pp. 7146-7154